ArticleAdvances in rheumatology (London, England)2025
Cytokine-induced memory-like natural killer cells in systemic lupus erythematosus patients.
Article in Advances in rheumatology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNatural killer (NK) cell abnormalities may contribute to the pathogenesis of systemic lupus erythematosus (SLE). Interleukin (IL)-15, an immunoregulatory cytokine crucial for NK survival, is overexpressed in SLE patients. Cytokine-induced memory-like (CIML) NK cells, which are NK cells pre-activated with short-term IL-12+IL-15+IL-18 followed by incubation with low-dose IL-15 for 1-2 weeks, exhibit enhanced NK effector function upon re-stimulation.
methodsWe collected blood samples from 54 patients with SLE and 38 healthy volunteers. Extended IL-15 stimulation of peripheral blood mononuclear cells (PBMCs) was performed. Surface marker analysis, IFN-γ, TNF-α production, and cytotoxicity evaluation were conducted. Next, we generated CIML NK cells by culturing PBMCs with IL-12+IL-15+IL-18. The influence of short-term and long-term IL-15 treatment on CIML NK cells was assessed. Finally, we examined the effect of re-stimulation with IL-12+IL-15+IL-18 on CIML NK cells from SLE patients and healthy controls. Cytotoxicity, CD107a degranulation, and surface marker expression were analyzed.
resultsWe found that 1. The percentage of CD3-CD56+ NK cells was initially decreased in SLE patients compared with controls, but was enhanced after long-term IL-15 incubation; 2. Long-term IL-15 stimulation facilitated the conversion from CD3-CD56dim to CD3-CD56bright NK cells; 3. CIML NK cells were successfully generated in SLE patients, showing increased percentages of CD3-CD56+ and CD3- CD56bright NK cells and a concomitant decrease in CD3-CD56dim NK cells; 4. SLE CIML NK cells showed decreased IFN-γ, CD69, CD94, NKG2A, NKG2C, NKP30, NKP44, NKP46, and granzyme B expression compared with healthy controls; 5. On day 8, re-stimulation with IL-12+IL-15+IL-18 further enhanced the expression of IFN-γ, CD69, CD94, NKG2A, perforin, and granzyme B expression on SLE CIML NK cells; 6. Granzyme B expression in SLE CIML NK cells was higher on day 8 than on day 15.
conclusionOur findings revealed phenotypic differences and functional deficiencies in SLE CIML NK cells. Further investigation into the role of SLE CIML NK cells in providing antiviral and anti-tumor responses is warranted. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.